ALNY – Alnylam Pharmaceuticals, Inc.
Float Short %
4.02
Margin Of Safety %
-13
Put/Call OI Ratio
0.46
EPS Next Q Diff
0.93
EPS Last/This Y
7.17
EPS This/Next Y
4.98
Price
336.32
Target Price
463.12
Analyst Recom
1.62
Performance Q
-27.28
Upside
-76.5%
Beta
0.35
Ticker: ALNY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | ALNY | 357.75 | 0.56 | 0.14 | 23608 |
| 2026-01-26 | ALNY | 361.29 | 0.56 | 0.03 | 23650 |
| 2026-01-27 | ALNY | 354.78 | 0.56 | 0.63 | 23727 |
| 2026-01-28 | ALNY | 349.44 | 0.55 | 0.08 | 23868 |
| 2026-01-29 | ALNY | 346.67 | 0.55 | 0.67 | 24147 |
| 2026-01-30 | ALNY | 337.85 | 0.55 | 0.20 | 24400 |
| 2026-02-02 | ALNY | 338.91 | 0.54 | 0.12 | 24837 |
| 2026-02-03 | ALNY | 351.8 | 0.55 | 0.25 | 25394 |
| 2026-02-05 | ALNY | 330.62 | 0.56 | 0.44 | 25584 |
| 2026-02-09 | ALNY | 319.85 | 0.53 | 0.06 | 26408 |
| 2026-02-10 | ALNY | 322.74 | 0.52 | 0.59 | 26758 |
| 2026-02-11 | ALNY | 321.93 | 0.52 | 0.05 | 26829 |
| 2026-02-12 | ALNY | 308.08 | 0.51 | 0.43 | 27334 |
| 2026-02-13 | ALNY | 314.21 | 0.47 | 0.26 | 27875 |
| 2026-02-17 | ALNY | 332.77 | 0.46 | 0.30 | 27864 |
| 2026-02-18 | ALNY | 332.42 | 0.46 | 0.45 | 28162 |
| 2026-02-19 | ALNY | 338.37 | 0.46 | 0.07 | 28159 |
| 2026-02-20 | ALNY | 336.23 | 0.46 | 0.08 | 28319 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | ALNY | 357.86 | 2396.2 | 651.8 | 4.96 |
| 2026-01-26 | ALNY | 361.31 | 2396.2 | 686.9 | 4.96 |
| 2026-01-27 | ALNY | 354.89 | 2396.2 | 664.3 | 4.96 |
| 2026-01-28 | ALNY | 349.51 | 2396.2 | 666.8 | 4.96 |
| 2026-01-29 | ALNY | 346.69 | 2396.2 | 672.3 | 4.96 |
| 2026-01-30 | ALNY | 337.88 | 2396.2 | 657.7 | 4.96 |
| 2026-02-02 | ALNY | 338.73 | 2396.2 | 680.8 | 4.96 |
| 2026-02-03 | ALNY | 351.73 | 2394.9 | 710.3 | 4.96 |
| 2026-02-04 | ALNY | 351.97 | 2394.9 | 679.6 | 4.96 |
| 2026-02-05 | ALNY | 331.20 | 2394.9 | 629.9 | 4.96 |
| 2026-02-06 | ALNY | 327.93 | 2394.9 | 670.8 | 4.96 |
| 2026-02-09 | ALNY | 319.89 | 2394.9 | 658.1 | 4.96 |
| 2026-02-10 | ALNY | 322.66 | 2394.9 | 686.1 | 4.96 |
| 2026-02-11 | ALNY | 321.89 | 2394.9 | 676.4 | 4.96 |
| 2026-02-12 | ALNY | 308.17 | 2394.9 | 642.5 | 4.96 |
| 2026-02-13 | ALNY | 314.47 | 2394.9 | 700.0 | 4.96 |
| 2026-02-17 | ALNY | 332.62 | 17827.3 | 265.7 | 9.70 |
| 2026-02-18 | ALNY | 332.71 | 16990.9 | 503.5 | 9.61 |
| 2026-02-19 | ALNY | 339.41 | 16990.9 | 525.9 | 9.61 |
| 2026-02-20 | ALNY | 336.32 | 15972.7 | - | 9.56 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | ALNY | -6.35 | 2.11 | 4.26 |
| 2026-01-26 | ALNY | -6.35 | 2.10 | 4.26 |
| 2026-01-27 | ALNY | -6.35 | 2.10 | 4.26 |
| 2026-01-28 | ALNY | -6.35 | 2.10 | 4.29 |
| 2026-01-29 | ALNY | -6.35 | 2.10 | 4.29 |
| 2026-01-30 | ALNY | -6.35 | 2.10 | 4.29 |
| 2026-02-02 | ALNY | -6.35 | 2.14 | 4.29 |
| 2026-02-03 | ALNY | -6.35 | 2.14 | 4.29 |
| 2026-02-04 | ALNY | -6.35 | 2.14 | 4.29 |
| 2026-02-05 | ALNY | -5.83 | 2.14 | 4.30 |
| 2026-02-06 | ALNY | -5.83 | 2.14 | 4.30 |
| 2026-02-09 | ALNY | -5.83 | 2.76 | 4.30 |
| 2026-02-10 | ALNY | -5.83 | 2.76 | 4.30 |
| 2026-02-11 | ALNY | -5.83 | 2.76 | 4.08 |
| 2026-02-12 | ALNY | -5.83 | 2.76 | 4.03 |
| 2026-02-13 | ALNY | -12.00 | 2.76 | 4.03 |
| 2026-02-17 | ALNY | -9.86 | 1.73 | 4.02 |
| 2026-02-18 | ALNY | -10.91 | 1.73 | 4.02 |
| 2026-02-19 | ALNY | -10.91 | 1.73 | 4.02 |
| 2026-02-20 | ALNY | -9.12 | 1.73 | 4.02 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.25
Avg. EPS Est. Current Quarter
1.59
Avg. EPS Est. Next Quarter
2.18
Insider Transactions
-9.12
Institutional Transactions
1.73
Beta
0.35
Average Sales Estimate Current Quarter
1128
Average Sales Estimate Next Quarter
1330
Fair Value
292.35
Quality Score
90
Growth Score
62
Sentiment Score
95
Actual DrawDown %
32.1
Max Drawdown 5-Year %
-42.5
Target Price
463.12
P/E
148.95
Forward P/E
30.15
PEG
0.36
P/S
12.01
P/B
56.39
P/Free Cash Flow
95.81
EPS
2.26
Average EPS Est. Cur. Y
9.56
EPS Next Y. (Est.)
14.54
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
8.45
Relative Volume
0.88
Return on Equity vs Sector %
10.7
Return on Equity vs Industry %
28.2
EPS 1 7Days Diff
-1
EPS 1 30Days Diff
-1.68
EBIT Estimation
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2500
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading